Echo Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Cash flows from operating activities:
Net loss
Depreciation and amortization
Amortization of deferred financing costs
Share-based compensation, net
Fair value of common stock issued for services
Non-cash (gain) loss on extinguishment of debt
Gain on revaluation of derivative warrant liability
Non-cash loss on extinguishment of debt
Non-cash interest expense
Non-cash loss on disposal of assets
Non-cash debt financing costs
Cash received from lessor as a lease incentive
Warrant repricing charged to legal expense
Loss on disposals of assets
Impairment charge
Financing loss
Amortization of discount on note payable
Accounts receivable
Prepaid expenses and other
Deposits and other assets
Accounts payable
Deferred revenue from licensing arrangements
Accrued and other
Net cash used in operating activities

Cash Flows from Investing Activities:
Purchase of property and equipment
(Increase) decrease in restricted cash
Decrease in security deposit
Proceeds on disposal of property and equipment
Net cash provided by (used in) investing activities
Cash Flows From Financing Activities:
Proceeds from Platinum note payable
Proceeds from Montaur note payable
Repayment of credit facility
Proceeds from equity issuances
Proceeds from bridge loans
Principal payments on capital lease obligations
Proceeds from issuance of Series D Convertible Preferred Stock and warrants, net of expenses
Proceeds from bridge notes
Repayment of bridge notes
Proceeds from the exercise of warrants
Proceeds from exercise of stock options
Capital contribution
Net cash provided by financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year

Supplemental disclosure of cash flow information:
Cash paid for interest
Accretion of dividend on Series B Perpetual Redeemable Preferred Stock
Cash paid for income taxes
Deemed dividend on beneficial conversion feature of convertible preferred stock
Issuance of common stock in settlement of short term note
Conversion of notes payable and accrued interest into Series D Convertible Preferred Stock
Director’s fees payable offset against prepaid insurance
Accrued legal fees settled with stock
Security deposit offset against accounts payable
Conversion of convertible preferred stock into Common Stock at par value
Redemption of Series B Perpetual Redeemable Preferred Stock for Series C Preferred Stock in connection with October 27, 2011 warrant exercises
Reclassification of derivative warrant liability to additional paid-in capital
Fair value of warrants included in stock issuance costs
Common Stock subscription receivable
Fair value of restricted stock issued in connection with settlement agreement
Fair value of Common Stock issued in connection with settlement agreement
Cancellation of restricted Common Stock
Deemed dividend on repricing of warrants
Fair value of Commitment Warrant issued in connection with debt financing
Fair value of Draw Warrant issued for note payable recorded as discount
Fair value Draw Warrant issued for note payable recorded as debt financing costs

Comments